CTIS2023-504434-22-00招募中1 期
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi) - AK112-301
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 481
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1, Life expectancy = 3 months, Locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous NSCLC confirmed by histology or cytology, inoperable and unable to receive radiotherapy and chemotherapy, The tumor histology, cytology or blood test confirmed the presence of EGFR activating mutations before enrollment, Have previously received EGFR-TKI treatment and the treatment has failed, Subjects have at least one measurable non-brain tumor lesion per RECIST v1.1, Major organ function prior to treatment meets the criteria defined in Protocol, Patients of childbearing potential must agree to use highly effective contraceptive measures
排除标准
- •Histological or cytological pathology confirmed the presence of small cell carcinoma components, or the main component is squamous cell carcinoma, Active autoimmune disease requiring systemic treatment within 2 years prior to the start of study treatment, There is a history of major diseases 1 year prior to the first dose, Medical history of gastrointestinal perforation or gastrointestinal fistula within 6 months prior to the first dose, Received chest radiation therapy prior to the first dose, Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage, Active or previously documented inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), There are reports confirming the existence of other driver gene mutations with known drug treatments, Subjects who received any prior treatments targeting the mechanism of tumor immunity, The subject has received systemic anti-tumor therapy other than EGFR-TKI, Currently enrolled in any other clinical study, Received EGFR-TKI treatment, palliative local treatment, non-specific immunomodulatory treatment within 2 weeks prior to the first dose; and Chinese herbal medicine or traditional Chinese medicinal products with anti-tumor indications within 1 weeks prior to the first dose, Tumor surrounds important blood vessels or has obvious necrosis, cavitation, or invades surrounding important organs and blood vessels, Symptomatic central nervous system metastases, Active malignancies within the past 3 years, with the exception of tumors in this study and cured local tumors
研究者
相似试验
已完成
不适用
A Phase 2 Trial to Evaluate the Efficacy and Safety of Candesartan/Amlodipine Combined or Alone and Select Better Dose of CKD-330 in Patients with Essential HypertensioDiseases of the circulatory systemKCT0001846Chong Kun Dang456
已完成
3 期
Clinical trial to demonstrate the immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in healthy adultsCTRI/2021/09/036860GCChemie Pharmie Ltd268
进行中（未招募）
1 期
A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography (qEEG) and Event-Related Potentials (ERP) in Patients with Mild-to-Moderate Alzheimer's DiseaseMedDRA version: 12.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseAlzheimer's DiseaseEUCTR2010-018273-38-FRAstraZeneca AB40
进行中（未招募）
3 期
A Phase III Study to check the Safety and efficacy of the PCV 13 Vaccine in Healthy Infants in India in prevention of Pneumococcal disease caused by Streptococcus pneumonia.CTRI/2022/11/047443G C Chemie Pharmie Ltd
进行中（未招募）
不适用
A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV MelanomaRevised Protocol 1, incorporating Amendment 2 - version 4.0, dated 15-Feb-06Previously treated unresectable Stage III or IV MelanomaEUCTR2005-003265-16-BEBristol-Myers Squibb International Corporation240